The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.

Schulzer, M

The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. [electronic resource] - Annals of neurology Dec 1992 - 795-8 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0364-5134

10.1002/ana.410320614 doi


Humans
Models, Statistical
Parkinson Disease--drug therapy
Selegiline--therapeutic use
Survival Analysis